PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
- 1.3k Downloads
For the last decade PET and PET/CT with 11C-choline have been proposed for the evaluation of prostate cancer (PC), but the diagnostic performance of 11C-choline PET/CT is still a matter of debate. We performed a comprehensive review of the most important clinical application of 11C-choline PET, restaging of patients with biochemical relapse, following a rigorous methodological approach and including assessment of the risk of bias. We conducted a systematic review and meta-analysis of the literature assessing 11C-choline PET/CT for its accuracy in the diagnosis and ability to detect the site of recurrence of PC in the restaging of patients with biochemical recurrence after initial treatment with curative intent.
We performed a comprehensive literature search of PubMed and the Cochrane Library to determine the accuracy for the detection of the site of recurrence (prostate bed recurrences, metastatic spread to locoregional pelvic lymph nodes or distant metastases). Only studies with a reference standard (for prostatic bed histopathology, for histopathology or biopsy of distant metastases or a composite reference standard with clinical follow-up of at least 12 months, correlative imaging and clinical data) were included.
Overall 425 studies were retrieved, of which 43 were judged as potentially relevant and 29 with 2,686 participants were finally included. Of these 29 studies, 18 reported results for any relapse, All 18 studies, with a total of 2,126 participants, reported detection rates. The pooled rate was 62 % (95 % CI 53 – 71 %). Of the 18 studies, 12 with 1,270 participants reported useful data to derive sensitivity and specificity. The pooled sensitivity was 89 % (95 % CI 83 – 93 %) and the pooled specificity was 89 % (95 % CI 73 – 96 %). Of 11 studies reporting results for local relapse, 9 with 993 participants reported detection rates. The pooled rate was 27 % (95 % CI 16 – 38 %). Six studies with 491 participants reported sensitivity and specificity. The pooled sensitivity was 61 % (95 % CI 40 – 80 %) and the pooled specificity was 97 % (95 % CI 87 – 99 %). Ten studies reported results for lymph nodes and distant metastases. For nodal disease, 7 studies with 752 participants reported detection rates. The pooled rate was 36 % (95 % CI 22 – 50 %). For bone metastases, 8 studies with 775 participants reported detection rates. The pooled rate was 25 % (95 % CI 16 – 34 %).
There is a significant amount of 11C-choline PET data published showing a high degree of consistency in inclusion criteria, acquisition protocols and scan interpretation criteria. Furthermore, the quality of the data derived limited to the same standard of reference was acceptable. Despite a high variability in the observed prevalence of any relapse, the diagnostic performance of 11C-choline PET was in line with previous meta-analyses. Our data confirm the very good accuracy of 11C-choline PET for detection of lymph node metastases and/or distant lesions in a single examination in patients with biochemical relapse.
KeywordsProstate cancer Positron emission tomography 11C-Choline
Compliance with ethical standards
This study was partly funded by the EANM (honorarium to Silvia Minozzi) as part of a project to promote the approval of new tracers for clinical use.
Conflicts of Interest
This article does not describe any studies with human participants or animals performed by any of the authors.
- 7.Mohler JL, Armstrong AJ. NCCN clinical practice guidelines in oncology. Prostate cancer, version 1.2015. National Comprehensive Cancer Network; 2015.Google Scholar
- 8.Mottet N, Bellmunt J, Briers E, van den Bergh RCN, Bolla M, van Casteren NJ, et al. Guidelines on Prostate Cancer. Eur Soc Urol. 2015.Google Scholar
- 9.Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51–60. doi: 10.1016/j.eururo.2010.09.004.CrossRefPubMedGoogle Scholar
- 10.Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors). Cochrane handbook for systematic reviews of diagnostic test accuracy version 1.0. The Cochrane Collaboration, 2010.Google Scholar
- 11.Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74. doi: 10.1016/j.ijrobp.2006.04.029.CrossRefPubMedGoogle Scholar
- 14.Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011.Google Scholar
- 18.Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology. 2008;249:1017–25. doi: 10.1148/radiol.2492080038.CrossRefPubMedGoogle Scholar
- 19.Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, et al. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol. 2008;35:689–95. doi: 10.1016/j.nucmedbio.2008.05.006.CrossRefPubMedGoogle Scholar
- 23.Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, et al. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med. 2012;37:325–31. doi: 10.1097/RLU.0b013e31823363b0.CrossRefPubMedGoogle Scholar
- 25.Alongi F, Comito T, Villa E, Lopci E, Cristina I, Mancosu P, et al. What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients? Acta Oncol. 2014;53:990–2. doi: 10.3109/0284186X.2013.865078.CrossRefPubMedGoogle Scholar
- 26.Giovacchini G, Picchio M, Garcia-Parra R, Briganti A, Abdollah F, Gianolli L, et al. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med. 2014;55:233–41. doi: 10.2967/jnumed.113.123380.CrossRefPubMedGoogle Scholar
- 28.Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer. 2014;12:106–10. doi: 10.1016/j.clgc.2013.08.002.CrossRefPubMedGoogle Scholar
- 30.Bertagna F, Abuhilal M, Bosio G, Simeone C, Rossini P, Pizzocaro C, et al. Role of (11)C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation. Jpn J Radiol. 2011;29:394–404. doi: 10.1007/s11604-011-0570-1.CrossRefPubMedGoogle Scholar
- 31.Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA, et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys. 2010;77:160–4. doi: 10.1016/j.ijrobp.2009.04.090.CrossRefPubMedGoogle Scholar
- 32.Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394–400. doi: 10.2967/jnumed.108.061507.CrossRefPubMedGoogle Scholar
- 33.Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55–63. doi: 10.1007/s00259-010-1604-0.CrossRefPubMedGoogle Scholar
- 34.Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, et al. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging. 2014;41:878–86. doi: 10.1007/s00259-013-2655-9.CrossRefPubMedGoogle Scholar
- 35.Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, et al. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2013;40:149–55. doi: 10.1007/s00259-012-2272-z.CrossRefPubMedGoogle Scholar
- 36.Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R, et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging. 2014;41:2222–31. doi: 10.1007/s00259-014-2872-x.CrossRefPubMedGoogle Scholar
- 37.de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32–8, discussion 38–9.Google Scholar
- 38.Fuccio C, Castellucci P, Schiavina R, Guidalotti PL, Gavaruzzi G, Montini GC, et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81:e893–6. doi: 10.1016/j.ejrad.2012.04.027.CrossRefPubMedGoogle Scholar
- 41.Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:1106–16. doi: 10.1007/s00259-010-1403-7.CrossRefPubMedGoogle Scholar
- 42.Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55:223–32. doi: 10.2967/jnumed.113.123018.CrossRefPubMedGoogle Scholar
- 43.Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23. doi: 10.1007/s00259-007-0581-4.CrossRefPubMedGoogle Scholar
- 44.Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. Clin Nucl Med. 2013;38:e342–5. doi: 10.1097/RLU.0b013e31829af913.CrossRefPubMedGoogle Scholar
- 45.Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)C-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013;189:1308–13. doi: 10.1016/j.juro.2012.10.069.CrossRefPubMedGoogle Scholar
- 46.Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, et al. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2014;32:38 e9–16.Google Scholar
- 47.Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337–40. doi: 10.1097/01.ju.0000056901.95996.43.CrossRefPubMedGoogle Scholar
- 48.Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:13–26. doi: 10.1007/s00259-011-1920-z.CrossRefPubMedGoogle Scholar
- 51.Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786–93. doi: 10.1111/j.1464-410X.2007.07083.x.CrossRefPubMedGoogle Scholar
- 52.Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE, et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int. 2008;81:191–7. doi: 10.1159/000144059.CrossRefPubMedGoogle Scholar
- 53.Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer. World J Urol. 2013;31:319–23. doi: 10.1007/s00345-012-0908-z.CrossRefPubMedGoogle Scholar
- 55.Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9. doi: 10.1016/j.eururo.2007.03.032.CrossRefPubMedGoogle Scholar
- 56.Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102:446–51. doi: 10.1111/j.1464-410X.2008.07592.x.CrossRefPubMedGoogle Scholar
- 60.Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, et al. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14:671. doi: 10.1186/1471-2407-14-671.PubMedCentralCrossRefPubMedGoogle Scholar
- 61.Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess. 2007;11:iii, ix–51.Google Scholar
- 62.Gurusamy KS, Davidson BR. Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2015:CD011515. doi: 10.1002/14651858.CD011515.
- 63.Crawford F, McIntosh H, Dozier M, Brush J, Glanville JM, Dunlop MG, et al. FDG PET-CT imaging for pre operative staging in patients with colorectal cancer. Cochrane Database Syst Rev. 2012:CD009630. doi: 10.1002/14651858.CD009630.
- 67.Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med. 2014;52(5):725–33. doi: 10.1515/cclm-2013-0675.